Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Madagascar Protocol to Treat COVID 19
Two Mechanism:
Artemisia annua Targeting Ferritin & Ivermectin Stopping Viral Replication
Dr. Jose Luis Abreu (Author)
Dr. Jennifer Hibberd (Editor)
Abstract. In this study, the following topics are discussed in a chained analysis of events:
Hydrogen peroxide, hydrogen peroxide in the human body, hydrogen peroxide and the role of reactive
oxygen species in antiviral defense, ferritin and inflammation, ferritin, inflammation and covid-19, silent
hypoxia, ferritin, inflammation, and multi-organ injury in covid-19 (sudden death?), artemisia annua(artemisinin) targeting ferritin, immunoregulatory and anti-inflammatory actions of artemisinin and its
derivatives, ivermectin and viral inhibition, and the Madagascar protocol with an updated analysis. The
Madagascar Protocol comprises the use of Artemisia annua and ivermectin as a combination therapy
to treat COVID 19. Both have proven to be successful in the treatment of the virus. This article
discusses the scientific evidence that supports the protocol.
Keywords. Madagascar Protocol, Artemisia annua, Ivermectin, Ferritin, COVID-19.
Introduction
D’Alessandro et al (2020) have reported that in recent decades, drugs used to treat malaria infection
have been shown to be beneficial for many other diseases, including viral infections. In particular, they
have received special attention due to the lack of effective antiviral drugs for use against new emerging
viruses (i.e., HIV, dengue virus, chikungunya virus, ebola virus, etc.) or against classic infections due
to drug-resistant viral strains (i.e., human cytomegalovirus). They reviewed the in vitro/in vivo andclinical studies conducted to evaluate the antiviral activities of four classes of antimalarial drugs:
Artemisinin derivatives, aryl-aminoalcohols, aminoquinolines, and antimicrobial drugs.
Antimalarial drugs are usually divided based on the chemical structure or the source of the drugs. Mostof them derive from traditional medicine and plants. They present different modes and various
mechanisms of action, which are often still not elucidated. Furthermore, due to the complexity of these1

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

molecules, additional side activities have been reported. For these reasons, antimalarial drugs havebeen studied, proposed, and sometimes used for the treatment of other pathologies, such as cancer,
autoimmune diseases, and non-malaria infectious diseases. Moreover, the geographic overlaps
between malaria and viral-related diseases have led to the consideration of possible use of antimalarial
drugs as new antiviral drugs. Finally, the lack of new effective antiviral drugs and vaccines against
many viral infections has strengthened interest in the potential antiviral activity of antimalarial drugs(D’Alessandro et al 2020).
In their study, D’Alessandro et al (2020) discussed the use and the efficacy of the principal antimalarial
drugs used against human viruses. These antimalarial drugs are divided into four main groups:
Artemisinin derivatives, arylaminoalcohols, aminoquinolines, and antimicrobial drugs. Based on
detailed documented research D’Alessandro et al (2020) concluded that the use of antimalarial drugs
might be useful, especially in cases of antiviral resistance, and in light of the emergence of many viruses
against which effective drugs are not available.
Regarding the effectiveness of Ivermectin, there are many examples and scientific evidence alreadypublished and made public in different communication networks. For example, a group of senior doctors
with vast clinical experience met on July 19, 2020 under the aegis of Academy of Advanced Medical
Education (Bombay, India). The panel looked at Ivermectin, one of the old molecules, and evaluatedits use in COVID 19 (Novel Coronavirus Disease 2019) management. After a critical panel discussion,
all the attending doctors came to a conclusion that Ivermectin can be a potential molecule forprophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupledwith effective cost, availability and good tolerability and safety (Vora, Arora, and Behera, 2020).
Additionally, TrialSite (2020) recently communicated that the president of one of Dominican Republic’s
largest private health systems (Rescue Group), Dr. José Natalio Redondo, reported that at least 6,000
COVID-19 positive patients have been treated, with excellent results, using Ivermectin.
It has been reported that Artemisia annua and Ivermectin has been used successfully for the treatmentof malaria in Africa. Coincidentally, the Madagascar Protocol comprises the use of Artemisia annua
and Ivermectin as a combination therapy to treat COVID 19. Both have proven to be successful in thetreatment of the virus.

2

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

This article discusses the scientific evidence that supports the efficacy of the Madagascar Protocol.
The following topics are discussed in a chained analysis of events:
Hydrogen peroxide in the human body, hydrogen peroxide and the role of reactive oxygen species inantiviral defense, ferritin and inflammation, ferritin, inflammation and covid-19, silent hypoxia, ferritin,
inflammation and multi-organ injury in covid-19 (sudden death?), artemisia annua (artemisinin)
targeting ferritin, immunoregulatory and anti-inflammatory actions of artemisinin and its derivatives,
ivermectin and viral inhibition, and the Madagascar protocol with an updated analysis.
Hydrogen Peroxide
Biocides, at a high concentration, cause massive cellular damage at a macromolecular level, withdisparate mechanisms of action depending on the chemical nature of the biocide. Oxidative biocides,
such as chlorine and hydrogen peroxide (H2O2) remove electrons from susceptible chemical groups,
oxidizing them, and they, themselves, become reduced in the process. At a cellular level, low levels ofoxidation can be a highly reversible process and prokaryotic organisms have evolved many defenses
against these effects. At the proper biocide concentrations, these defense mechanisms can be
overwhelmed, with significant surface cell wall and intracellular damage. Oxidizing agents are usually
low molecular weight compounds and are considered to easily pass through cell walls/membranes,
whereupon they are able to react with internal cellular components, leading to apoptotic and necrotic
cell death. Alternatively, they can severely damage microbial structure causing the release of
intracellular components, which are then oxidized (Finnegan, 2020).
Although biochemical mechanisms of action may differ between oxidative biocides, the physiologicalactions are very similar. Oxidative biocides are proposed to have multiple targets within a cell as wellas in almost every biomolecule. These include peroxidation and disruption of membrane layers,oxidation of oxygen scavengers and thiol groups, enzyme inhibition, oxidation of nucleosides, impairedenergy production, disruption of protein synthesis and, ultimately, cell death (Finnegan, 2020).
The chemistry of organic peroxides has more than a hundred-year history. Currently, organic peroxides
are widely used as oxidizing agents and initiators for free-radical reactions both in industry and in thelaboratory. These compounds are produced and involved in various natural and biological processes
and have been explored extensively as antimalarial agents, anthelmintics, and anticancer drugs.
3Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Currently, the progress in the chemistry of organic peroxides is mainly a result of their biological activity
and pharmaceutical application. The search for effective antimalarial and antihelminthic drugs is themain challenge of medicinal chemistry of peroxides (Yaremenko et al, 2016).
Compounds with high antimalarial, antihelminthic, antitumor and antiviral activities were found among
natural, semisynthetic, and synthetic peroxides. The main biologically active frame of these compounds
includes five-membered 1,2-dioxolane, 1,2,4-trioxolane, and six-membered 1,2-dioxane, 1,2-dioxene,
1,2,4 trioxane cycles. The naturally occurring peroxide artemisinin and its semisynthetic derivatives,artemether, arteether, and artesunate, are applied on a large scale for malaria treatment (Yaremenko
et al, 2016).
Hydrogen Peroxide in The Human Body
Peroxides are widely used in various areas of life. The traditional and the most developed field is theapplication of peroxides as radical initiators in industrial processes in the manufacture of polymers fromunsaturated monomers: styrenes, butadienes, chlorovinyls, ethylenes, acrylates, as well as in crosslinking of silicone rubbers, acrylonitrile-butadiene rubbers, fluororubbers, polyethylene, ethylenepropylene copolymer, etc. Hydrogen peroxides are active components of antiseptics and disinfectants(Vil’ et al, 2017).
It has been explained by Halliwell, Clement & Long (2000) that hydrogen peroxide (H2O2) is a paleblue covalent liquid, freely mixable with water and apparently able to cross cell membranes, although
the pathways it uses to traverse have not been identified. Multiple references have determined high(usually ≥50 μM) levels of H2O2 as being cytotoxic to a wide range of animal, plant and bacterial cells
in culture, although LD50 values and the mode of cell death induced, apoptosis or necrosis, dependon the cell type used, its physiological state, length of exposure to H2O2, the H2O2 concentration, andthe cell culture media employed. It is generally thought that H2O2 is very toxic in vivo and must be
rapidly eliminated, employing enzymes such as catalases, peroxidases (especially glutathione
peroxidases) and thioredoxin-linked systems.
The levels of H2O2 at or below 20-50 μM seem to have limited cytotoxicity to most cell types. Indeed,
there is a growing research showing that H2O2 can be used as an inter- and intra-cellular signaling
molecule. The role of H2O2 as a second messenger in the activation of NFkB in some, but not all, cell4

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

types has been elucidated. Other evidence of the signaling roles for H2O2 have been found. Thesemay be good reasons not to eliminate all the H2O2 generated in vivo, its use in physiological signalingmechanisms is important. At sites of inflammation, H2O2 generated by activated phagocytes appears
to modulate the inflammatory process, e.g. by up-regulating expression of adhesion molecules,
controlling cell proliferation or apoptosis and modulating platelet aggregation (Halliwell, Clement &Long, 2000).
The Fenton reaction, a process of oxidation of organic molecules by Fe and H2O2, is very common in
the biological system, first described by H. J. H. Fenton in 1894. Hydrogen peroxide can contribute to
Fenton chemistry not only by being one of the substrates but also by liberating iron from heme proteins
and reducing iron in the inflammation process. The data presented by Halliwell, Clement & Long, 2000,
emphasize the importance of metal ion sequestration in preventing the toxicity of H2O2 in vivo bydecreasing the occurrence of Fenton chemistry.
Mentel' et al (1977) reported that the effect of H2O2 on adenovirus types 3 and 6, adeno-associatedvirus type 4, rhinoviruses 1A, 1B, and type 7, myxoviruses, influenza A and B, respiratory syncytial
virus, strain long, and coronavirus strain 229E were studied in vitro, using different H2O2
concentrations and times of exposure. A 3 % concentration of H2O2 inactivated all the viruses being
studied within 1--30 min. Coronavirus and influenza viruses were found to be most sensitive.
Reoviruses, adenoviruses and adeno-associated virus were relatively stable. Hydrogen peroxide wasfound to be a convenient means for virus inactivation.
Hydrogen Peroxide and the Role of Reactive Oxygen Species in Antiviral Defense
Skulachev (1998), from Lomonosov Moscow State University, hypothesized that reactive oxygen
species (ROS) including O2- , H2O2, OH-, are generated in the cell as the result of "parasitic" chemical
reactions of molecular oxygen with the enzymes and coenzymes of the initial and middle parts of therespiratory chain. ROS are also generated by specific enzymes which oxidize certain substrates by O2
generating O2 -· or H2O2.
The list of pathologies associated with a dramatic increase in the level of ROS include viral infections(Akaike, Suga, and Maeda, 1998). This is not limited to the altered balance between the parasitic
reactions generating ROS and ROS inactivation processes. Maeda et al. demonstrated that infection
5Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557Xof mice with influenza virus induces strong activation of xanthine oxidase in the lung (the rate of thexanthine oxidase reactions is increased by 2-3 orders of magnitude). A similar effect was also detectedin animals infected with cytomegalovirus (Skulachev, 1998).
Xanthine oxidase is the enzyme which catalyzes oxidation of xanthine and hypoxanthine by molecularoxygen. Unlike most oxidases which generate water from O2, xanthine oxidase converts O2 into O2 and H2O2. So, it is like NADPH-oxidase of the plasma membrane of phagocytes, which reduces
oxygen to superoxide (Henderson and Chappell, 1996 in Skulachev, 1998).
In the case of phagocytes, O2 is their biological weaponry used to defend against pathogenic bacteria.
Apparently, ROS has a different role in the case of a viral infection. It was shown by Akaike et al (1996,
1998) that the outburst of xanthine oxidase by itself does not suppress the production of the viruses.
However, the virus can consider increased ROS as something dangerous. Certain viruses possess
specific mechanisms preventing an increase in the level of ROS during infection. For example, human
T-lymphotropic virus stimulates the formation of thioredoxin that is an important component of theantioxidant defense in the cell (Nakanura et al, 1995 in Skulachev, 1998). Skulachev (1996, 1997,1998) reported that ROS are known to actively induce apoptosis. Apoptosis is one of the ways to defend
against viral infection; infected cells commit suicide, thus killing the viruses.
Skulachev (1998) proposed the following hypothesis to explain the role of xanthine oxidase activationand increase in ROS during viral infection:
The initial relationship between ROS and viral infection (infection-disbalance of antioxidant defenseincrease in ROS-elimination of infected cells by ROS-induced apoptosis) was probably modified during
evolution so that the cell considers the appearance of a virus in the cytoplasm as a signal for ROS
production. This results in increase in ROS long before this increase becomes inevitable due to cellularpathology occurring during intensive replication of the virus inside the cell. Increase in ROS should
induce apoptosis in the infected cell before it becomes a source of massive infection for its neighbours.
Another important consequence of the suggested mechanism should include a possibility of inductionof apoptosis in the adjacent cells which are in direct contact with the infected cell and are especiallyprone to infection. This can result from the diffusion of one ROS, namely H2O2. Hydrogen peroxide isa small neutral molecule that easily penetrates through the biological membrane, similar to H2O.
Evidently, a front of elevated concentration of H2O2 would spread significantly faster around the6Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

infected cell than a front of viral particles formed in the very same cell. Hence, an apoptotic zone would
be formed around the cell which is a potential source of viral infection. This explains the phenomenonof bystanders, i.e., the cells that are not infected with the virus, but adjacent to the infected cells, thatare eliminated together with the infected cells. In humans and animals a superproduction of H2O2
occurs by xanthine oxidase in response to an intensive viral infection and it can be so potent that it
induces pathological effects by itself, and the virus plays only the trigger role. This hypothesis that thecell detects a virus and responds by an outburst of enzymatically generated ROS is supported by workof Falciani et al (1992).
Participation of ROS in apoptosis induced by viral infection was demonstrated for HIV by Staal et al(1990) and Roederer (1992), and for type I human T-cell leukoma virus by Yodoi and Uchiyama (1992)
and Furuke et al (1997). In the latter case, infected cells are significantly more susceptible to ROS thannormal ones.
Skulachev (1998) explained that one ROS, namely H2O2, is a real signal mediator, but its role is limited
to "bad news”. Hydrogen peroxide informs the cell that it should commit suicide. In such situations, any
danger of H2O2 as a precursor of toxic hydroxyl radicals seems unimportant because the cell is
supposed to die anyway.
For Rahbari et al (2017) hydrogen peroxide is an important antimicrobial agent but is also cruciallyinvolved in redox signaling and pathogen-host cell interactions. Hydrogen peroxide (H2O2) is one of
the most important cellular ROS and has crucial regulatory and signaling functions. Within cells, H2O2
can be produced by the mitochondrial respiratory chain, NADPH oxidases, through the enzymatic
detoxification of superoxide radicals by superoxide dismutase. The cytotoxic effects of H2O2 are wellknown and H2O2 is increasingly recognized as an important regulator of signal transduction in
eukaryotes. Hydrogen peroxide can act as a signaling molecule by regulating growth factors andcytokines to control cell division, differentiation, and migration. Moreover, H2O2 can diffuse throughbiological membranes and thus act as a long-range and fast acting signaling molecule. Furthermore,
H2O2 controls protein functions of redox-sensitive proteins by selectively oxidizing cysteine reactive
residues.

7

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Ferritin and Inflammation
Kernan, and Carcillo (2017) conducted studies on the correlation of hyperferritinemia (excess of ferritin)
and inflammation. These two researchers from University of Pittsburgh highlight that iron is an essential
component of hemoproteins, the principle proteins of oxygen transport in the cytochrome system of theelectron transport chain, liver metabolism in cytochrome p450s, as well as myoglobin and hemoglobin.
As such, maintaining physiologic levels of iron is essential with deficiency leading to impairment ofoxidative phosphorylation, oxygen delivery and subsequent metabolic failure.
In excess, iron can generate toxic free radicals via the Fenton reaction that directly damage cellular
proteins, lipids, and nucleic acids. In Figure 1, Kernan, and Carcillo (2017) illustrated this reaction,
where an occasional, but potentially damaging byproduct of aerobic metabolism, ferrous iron (Fe2+) is
oxidized to ferric (Fe3+), in the presence of hydrogen peroxide, producing a hydroxyl radical andhydroxide ion. Subsequently, iron metabolism is tightly regulated and actively sequestered by cells, inpart by ferritin molecules to limit induced oxidative stress.
Figure 1 shows the Fenton redox reaction. Ferrous, Fe2+ iron is readily convertible into ferric 3+ iron,along with the production of free hydroxyl radicals and hydroxide anion. These free radicals become asource of cellular oxidative stress, damaging DNA, lipids and proteins. Ferritin molecules help
sequester this free iron, preventing its participation in this reaction and subsequent free radicalmediated cellular damage (Kernan and Carcillo, 2017).
Figure 1. The Fenton redox reaction

Reference: (Kernan and Carcillo, 2017)
Free serum ferritin is increased in the setting of ongoing inflammation and there is also evidence that
supports a role for ferritin in modulating the immune response, via its induction of anti-inflammatory
cytokines and limitation of free radical damage. Alternatively, emerging work suggests a potential
causative role for ferritin in the inflammatory pathology of disease including rheumatologic,

8

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

immunologic, malignant and infectious disorders where levels not only track disease activity but may
be primary in pathology and are predictive of outcome (Kernan, and Carcillo, 2017).
Hyperferritinemia, regardless of the underlying pathology, as explained by Kernan, and Carcillo (2017),
is associated with high mortality. As a marker of significant macrophage activation, individuals
manifesting a hyperferritinemic phenotype show a typical pattern of reticuloendothelial system
activation and multiple organ dysfunction. Patients with inflammatory conditions can present
macrophage activation syndrome (MAS), including viral or bacterial sepsis, systemic inflammatory
response syndrome (SIRS), inherited immunologic disorders and rheumatologic disease. All arepathobiologically linked through a pattern of extreme hyperferritinemia and elevated cytokines including
TNF-α, IFN-γ, IL1-β, IL-10, IL-12, IL-6 and M-CSF. A subset of these individuals will go on to develop
such extreme systemic immune activation that they manifest multiple organ dysfunction and fulfill fiveof the eight diagnostic criteria: fever, splenomegaly, cytopenia, elevated triglycerides or decreased low
fibrinogen, elevated ferritin, low or absent NK cell activity hemophagocytosis, and increased soluble
IL-2 receptor (sCD25)
Kernan, and Carcillo (2017) concluded, in their study, that ferritin may be a key marker of a pathogenic
player in inflammatory pathology through its signaling as part of the innate immune response andmodulation of lymphocyte function. Clinical practice supports this role, as it can be used as both abiomarker of disease progress and prognosis as well as a target for therapeutic intervention.
Ferritin, Inflammation and COVID-19
Gómez-Pastora et al (2020) reported that patients infected with the novel coronavirus, designated assevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), develop the disease COVID-19,
which can cause severe pneumonia and damage the liver, heart and kidneys. The inflammatory
cytokine storm has been recognized as the primary cause of death, which is defined by the excessive
and uncontrolled release of pro-inflammatory cytokines, as has been reported in other infections
caused by pathogenic coronaviruses. For instance, inflammatory cytokines released by macrophages(IL-6, IL-10, and TNF-α) increase in patients with severe COVID-19 disease, resulting in damage tothe lungs and other organs.

9Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Little attention has been paid to ferritin, even though hyperferritinemia has been shown to be associatedwith complications in other viral diseases such as dengue fever. In order to determine if the circulating
ferritin concentration could be used to predict COVID-19 progression, and to associate
hyperferritinemia with the development of the cytokine storm, Gómez-Pastora et al (2020) reviewed
all published studies that documented serum ferritin levels in patients with severe and non-severe
COVID-19 disease, along with other inflammatory factors. Their research also included studies
reporting ferritin and cytokine levels in COVID-19 survivors and non-survivors.
The studies reported ferritin concentrations of COVID-19 patients only at the time of hospital admission.
It can be observed that the concentrations of ferritin are generally within the normal range (30–400μg/L) in patients with non-severe disease (according to the National Health Commission of China
guidelines for COVID-19 severity classification). However, hyperferritinemia (ferritin level > 400 μg/L),
was observed in patients with severe disease on admission. In fact, the average ferritin concentration
was > 800 μg/L for patients with severe disease. It was noted that ferritin levels on admission were
between 1.5 and 5.3 times higher in patients classified with severe disease in comparison to patientswith less-severe COVID-19 disease. The studies reported that non-survivors showed ferritin levels on
admission around 1400 μg/ L, which is between 3 and 4 times higher than that observed in survivors.
The studies also reported the levels of serum cytokines such as IL-6, which are especially high on
admission, in those patients developing severe disease. It was reported that both ferritin and IL-6
concentrations showed higher values in non-survivors in comparison to discharged patients throughout
the clinical course and increased as the patient deteriorated. When patients began to recover, theferritin and IL-6 concentrations decreased. This may confirm that hyperferritinemia is associated with
inflammatory states in SARS-CoV-2 infection, and therefore, ferritin can be a useful parameter topredict disease severity and the extent of the cytokine storm (Gómez-Pastora et al, 2020).
Active ferritin production during the course of inflammatory diseases can occur. Macrophages, which
produce cytokines and account for the majority of the immune cells in the lung parenchyma, might beresponsible for the secretion of serum ferritin. Moreover, ferritin synthesis can be induced by several
inflammatory stimuli including cytokines, such as IL-6. Interestingly, high IL-6 concentrations in COVID19 patients have been correlated to disease severity. Thus, ferritin might be actively secreted at thesite of infection (Gómez-Pastora et al, 2020).
10

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

A letter to the editor of Pan American Journal of Public Health, by -Vargas and Cortés (2020), reported
that ferritin is a key mediator of immune dysregulation, especially under extreme hyperferritinemia, via
direct immune-suppressive and pro-inflammatory effects, contributing to the cytokine storm. Fatal
outcomes by COVID-19 are accompanied by cytokine storm syndrome, thereby it has been suggested
that disease severity is dependent on the cytokine storm syndrome. They reviewed evidence
supporting the hypothesis that ferritin levels might be a crucial factor influencing the severity of COVID19.
Vargas and Cortés (2020) highlighted a study with 20 COVID-19 patients that showed individuals withsevere and very severe COVID-19. They exhibited increased serum ferritin level, with serum ferritin in
the very severe COVID-19 group significantly higher than in the severe COVID-19 group, 1006.16
ng/ml vs 291.13 ng/ml, respectively. They also identified another study revealing that in patients whodied of COVID-19, ferritin levels were high upon hospital admission and throughout the hospital stay.
The median values of serum ferritin levels after day 16 of hospitalization exceeded the upper limit ofdetection in these patients, suggesting that ferritin levels increased non-stop.
It was concluded by Vargas and Cortés (2020) that serum ferritin levels were closely related to theseverity of COVID-19. Finally, they reported that laboratory findings in patients with severe COVID-19
showed data consistent with cytokine storm involving elevated inflammatory markers, including ferritin,which has been associated with critical and life-threatening illness.
Abobaker (2000) reported strikingly high levels of ferritin in patients with the novel coronavirus disease2019 (COVID-19). Garrick and Ghio (2020 in Abobaker, 2000) explained that inflammation induced by
COVID-19 infection increases the hepcidin level, the main regulator of tissue iron store. It has been
proposed that the coronavirus (SARS-CoV-2) spike protein has hepcidin-like action, which means thatthe virus can directly increase ferritin level regardless of the inflammatory effect.
A high ferritin level has been linked with poor prognosis in COVID-19. The level of ferritin in COVID-19
non-survivors is higher than that of the survivors by twofold. Intracellular iron generates reactive oxygen
species in the lung by interacting with oxygen molecules which could predispose to the developmentof adult respiratory distress syndrome (ARDS) (Edeas, Saleh, and Peyssonnaux, 2020 in Abobaker,
2000). Intracellular iron and hyperferritinemia increase the risk of coagulopathy and oxidative stressand induce endothelial inflammation which could predispose to disseminated coagulation and11Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

multiorgan failure (Garrick and Ghio, 2020; (Edeas, Saleh, and Peyssonnaux, 2020, in Abobaker,
2000). It seems that hepcidin antagonists could offer a potential future possible approach in supportive
management of COVID-19. Iron-containing enzymes are required for viral replication, including
coronavirus. It is noted that coronavirus replication was suboptimal in iron-depleted cells comparedwith iron replete cells (Liu et al, 2020 in Abobaker, 2000).
Huang et al (2020) performed a comprehensive systematic literature search through electronic
databases. The outcome of interest for their study was the composite poor outcome, which comprises
mortality, acute respiratory distress syndrome, need for care in an intensive care unit, and severe
COVID-19. A total of 5350 patients were pooled from 25 studies. Huang et al (2020) found that a higher
serum ferritin level was independently associated with acute respiratory distress syndrome, mortality,
and severe COVID-19. This may lead to the notion of the presence of secondary hemophagocytic
lymphohistiocytosis (sHLH) in COVID-19. Hemophagocytic lymphohistocytosis is a condition of
hyperinflammation characterized by a cytokine storm causing fatal multi-organ failure. This condition ismost commonly triggered by viral infections, which might lead to a hypothesis of SARS-CoV-2 inducing
this hyperinflammatory syndrome. This meta-analysis showed that an elevated ferritin factor was
associated with a poor outcome in COVID-19.
Silent Hypoxia, Ferritin, Inflammation and multi-organ injury in Covid-19 (Sudden Death?)
Cavezzi, Troiani and Corrao (2020) reported that the Coronavirus disease-19 (COVID-19) has been
regarded as an infective-inflammatory disease, which affects mainly lungs, but also recently, a multiorgan involvement has been detected, with different pathways of injury. They suggested that ahemoglobinopathy, hypoxia and cell iron overload might have a possible additional role.
In this scenario, Cavezzi, Troiani and Corrao (2020) pointed out two potential pathophysiologicalmechanisms: (1) Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV- 2) interaction withhemoglobin molecule, through CD147, CD26 and other receptors located on erythrocyte and/or blood
cell precursors; (2) Hepcidin-mimetic action of a viral spike protein, inducing ferroportin blockage.
In addition, Cavezzi, Troiani and Corrao (2020) presented the following pathologic metabolic pathways,
derived from hemoglobin denaturation and iron metabolism dysregulation, as highlighted: (1) Decreaseof functioning hemoglobin; (2) Iron overload in cell/tissue (hyperferritinemia); (3) Release of free toxic
12

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

circulating heme; (4) Hypoxemia and systemic hypoxia; (5) Reduction of nitric oxide; (6) Coagulation
activation; (7) Ferroptosis with oxidative stress and lipoperoxidation; (8) Mitochondrial degeneration
and apoptosis
Concerning lung consequences, a systemic hypoxic state, with normal pulmonary tissue compliance,
has been highlighted in up to 80% of intensive care unit (ICU) patients exhibiting respiratory distress,
which led a few authors to question Acute Respiratory Distress Syndrome (ARDS) diagnosis. A typeof silent hypoxia is described in these patients, where they show progressively worse hypoxemia
associated with normal CO2. Normocapnia reflects normal pulmonary gas exchange. The primarysensor for respiratory distress is CO2 elevation. When CO2 increases, patients show relevant
respiratory symptoms at later stages only. Lastly, hyperferritinemia progressively affects alveolarcapillary/cell membrane integrity/permeability. Ultimately, inflammation, edema and lung cell necrosis
may complicate the pulmonary condition (Cavezzi, Troiani and Corrao, 2020).
By mimicking hepcidin action, SARSCoV-2 might remarkably increase circulating and tissue ferritin(mainly affecting liver, spleen, bone marrow and muscles), while inducing serum iron deficiency andlack of hemoglobin, by consequence. Cell iron overload is tolerated up to a threshold, as with silent
hypoxia (COVID-19 first phase). The increasing ferroptosis-linked multi-organ oxidative stress canprecipitate the inflammatory/immune over-response (Interleukine storm) in the later, most criticalstages. Recent laboratory data showed a relevantly lower hemoglobin level and higher ferritin levels in
non-surviving patients, over the survivors. Hyperferritinemia may induce a series of direct and indirect(via autoimmunity) injuries to most organs during COVID-19, such as coagulopathies, macrophageactivation syndrome, hemochromatosis-like liver injury, and other ferroptosis-driven syndromes(Cavezzi, Troiani and Corrao, 2020).
Viruses generally increase iron deposit, to favour their diffusion in host cells; conversely, our immune
system tends to control iron metabolism in case of infection, also through transferrin. This key-factor ofiron metabolism has ubiquitous receptors, which are used by many viruses to enter host cells. Possibly,
future research could elicit the transferrin receptor as another target of SARS-CoV-2 (Cavezzi, Troiani
and Corrao, 2020).
Cavezzi, Troiani and Corrao (2020) concluded that several organs are directly, or indirectly targeted by
SARS-CoV-2 and multiple pathomechanisms can be described to be immune/inflammatory type and13

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

linked to hypoxia and ferroptosis. Thromboembolism also seems to play a relevant role in later stages.
Overall, pathophysiological pathways seem to overlap in most cases. They found hemoglobinopathy
and iron dysmetabolism may induce a series of biological events, which objectively relate to the clinicalsyndromes highlighted during COVID-19.
Whether the original pathologic viral process begins in the lungs, with consequent general anemic
hypoxia and iron dysmetabolism, or vice versa, hemoglobin/iron dysmetabolism is the leading processthat results in multi-organ disease and further hypoxia, is a matter of urgent research (Cavezzi, Troiani
and Corrao, 2020).
Perricone et al (2020) studied COVID-19 as part of the hyperferritinemic syndromes and the role ofiron. It is well known that ferritin serves to bind iron molecules and to store iron in a biologically available
form for vital cellular processes while protecting proteins, lipids and DNA from the potential toxicity ofthis metal element. It has been shown that ferritin has different implications during inflammation. Ferritin
and its subunits, light chain ferritin (LHC) and heavy chain ferritin (HFC), showed in vivo and in vitro
immunomodulatory effects. Despite the acute rise of blood value of ferritin as part of the normal
systemic response to inflammation, a hyperferritinemic response is associated with a significantly
increased mortality in septic patients. Most probably, the synthesis of ferritin may be regulated bydifferent inflammatory cytokines such as IL-1β and IL-6 and serum ferritin is affected by upregulationof hepcidin whose production, in turn, is stimulated by pro-inflammatory cytokines, particularly IL-6.
Another variable to be considered in viral infections is the impact of iron overload. Iron is required forviral replication and other processes including mitochondrial function, ATP generation, DNA/RNA
synthesis and repair and cell survival/ferroptosis. For instance, the activity of the helicases of the
SARS-CoV for viral replication requires ATP hydrolysis that in turn needs the presence of iron. Iron
overload leads to a worse prognosis in viral infections and iron supplementation increases the mortality
in the patients, irrespectively of the anemic status. It is likely that SARS-CoV-2 requires iron for viral
replication and for its function (Perricone et al, 2020). This is among the rationales for Artemisia annua
therapy in COVID-19.
Perricone et al (2020) concluded in their studies that COVID-19 may be part of the hyperferritinemic
syndrome spectrum. This is possible because acute iron overload is caused by the rapid synthesis of
ferritin exceeding its iron incorporation rate. As a consequence of the pathogenic scenario linking iron,14

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

inflammation and infection, there is the need to find a possible therapeutic strategy to prevent cytokine
release syndrome in patients with COVID-19.
Artemisia annua Targeting Ferritin
According to Haynes et al (2013), the isolation of artemisinin from the traditional medicinal herb qīng
hāo (Artemisia annua), its characterization as a peroxide and preparation of the derivatives
dihydroartemisinin, artemether and artesunate, in the 1970s and 1980s by Chinese scientists under
the umbrella of Project 523, collectively represents one of the great events in medicine in the latter thirdof the 20th Century.
This collective information is used as a counterpoint to screen the validity of two of the prevailinghypotheses of drug action of artemisinins and synthetic peroxides. Namely (1). The ‘C-radical
hypothesis' wherein the peroxide undergoes 'bioactivation' by ferrous iron to generate C-radicals thatare thought to be the cytotoxic agents and (2).The 'heme hypothesis' wherein ferrous heme may
generate either the same type of 'cytotoxic' C-radical, or the peroxide forms heme adducts, thatapparently inherit the exquisite cytotoxicities of the parent peroxide in one way or another.
In general, little is precisely understood, as opposed to widely assumed, for the mechanism of drug
action of artemisinins and their synthetic peroxide analogue. Ali et al (2018) have described what iscalled the “artemisinin activation theory”. According to this theory, artemisinin is involved in an
activation to generate free radical species before its activation. This hypothesis is supported by the factthat artemisinin interacts with hemoglobin-bound iron through a covalent reaction for its activation.
However, later, it was assumed that ferrous heme (heme-Fe2+) may be the most competent activatorof artemisinin. Artemisinin activation models were categorized into two main groups: 1. Reductive
scission model and 2. Open peroxide model.
In reductive scission, ferrous-heme/non-heme exogenous Fe2+ is first attached to artemisinin by acovalent bond, causing the reductive scission of the endoperoxide bridge. This leads to the generationof oxygen-centered radicals, which subsequently self-arrange to give carbon-centered radicals. In
addition, iron–peroxide interaction occurs in different ways to form either primary carbon-centeredradicals (via C3–C4 bond scission) or secondary carbon-centered radicals (via 1,5 H-shifts).

15

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

The open peroxide model, on the other hand, suggests that the endoperoxide group of artemisinin
produces secondary carbon-centered radicals via a Fenton reaction involving the Fe2+ of hemoglobin.
The “artemisinin activation theory” has been supported by research findings showing that artemisinin
activity was significantly reduced in the presence of free radical scavengers and antioxidants, butenhanced in the presence of pro-oxidants (Ali et al, 2018). This is an important occurrence for a
combination treatment with high dose vitamin C, which acts as a pro-oxidant.
It has been found that artemisinin displays anti-inflammatory activity via inhibition of NF-κ B activity and
NALP3 inflammasome activation in mouse models. Artemisinin treatment attenuates the release of
TNF-α, IL-1β, and IL-6 through inhibition of the NF-κ B canonical pathway, therefore demonstrating
the capacity for inhibition of inflammation (Ali et al, 2018).
Tsuda et al (2018) studied the mechanisms of the pH- and Oxygen-Dependent Oxidation Activities ofArtesunate, and they found that artemisinin derivatives report inhibition of hypoxia-inducible factor-1α(HIF-1α) activation, and direct DNA injury. In addition, a reactive oxygen species (ROS) generation is
involved in many cases. The ROS generated by the coexistence of iron (II), artesunate, and molecularoxygen was a hydroxyl radical or hydroxyl radical-like ROS. Artesunate can reduce iron (III) to iron (II),which enables generation of ROS irrespective of the iron valence. They found that reduction from iron(III) to iron (II) was activated in the acidic rather than the neutral region and was proportional to thehydrogen ion concentration.
The mode of action of artemisinin depends on activation by cleavage of the endoperoxide bridge. There
are studies that have indicated that ferrous heme, hemin, free ferrous iron, and other iron-containing
species are strong activators of artemisinin. It was also found that mitochondria were directly involvedin both the activation and action of artemisinin, thus further linking artemisinin action to reactive
oxidative species (ROS) production and oxidative damage. Artemisinin activation is dependent on aheme-rich environment. For these reasons, the potential applications of artemisinin in anti-inflammatory
and anti-viral roles, among others, have been explored in earnest over the years (Wang et al, 2019).
Recent work has closely linked artemisinin-induced cytotoxicity to oxidative damage and lysosomal
function, with a focus on the role of iron in contributing to the iron-dependent form of cell death known
as ferroptosis. Lysosome-mediated degradation of ferritin under autophagy conditions (termed
16Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

ferritinophagy) releases free ferrous iron, which in turn contributes to both ferroptosis and iron-mediatedgeneration of ROS. Autophagy itself is a cellular process that is reportedly activated by artemisinin. It
is clear that the relationship between autophagy, lysosomal activity, free ferrous iron, and irondependent ferroptotic cell death following artemisinin exposure represents a major area of research inthe mechanism of artemisinin (Wang et al, 2019).
Yang et al (2014) demonstrated a novel mechanism for the mode of action of artesunate. Artesunate
accumulates in lysosomes and reacts with lysosomal iron. The activated artesunate then promotes
lysosomal function via enhancing V-ATPase assembly. One major source of iron for the cytotoxicity of
ART is attained from the degradation of ferritin by lysosomes.
Interestingly, Yang et al (2014) found that artesunate preferably accumulates in the lysosomes and isable to activate lysosomal function via promotion of lysosomal V-ATPase assembly. Furthermore, we
found that lysosomes function as the upstream of mitochondria in reactive oxygen species (ROS)
production. Importantly, we provided evidence showing that lysosomal iron is required for the lysosomal
activation and mitochondrial ROS production induced by ART.
The study of Yang et al (2014) demonstrated that artesunate treatment activates lysosomal function
and then promotes ferritin degradation, subsequently leading to the increase in the lysosomal ironwhich is utilized by artesunate for its cytotoxic effect. In conclusion, intracellular iron and ferritin
degradation is essential for artesunate-induced lysosomal activation and cell death.
Immunoregulatory and Anti-Inflammatory Actions of Artemisinin and its Derivatives
Shi et al (2015) describe artemisinin as a sesquiterpene lactone containing peroxide bridge. For them,T-cells play a pivotal role in the acquired immune reaction, which includes three fundamental steps.
First, TCR cross-linking drives T-cells from G0 to G1 transition and subsequent secretion of T-cellgrowth factor IL-2 and expression of high-affinity receptor IL-2R𝛼 chain (CD25). Second, throughautocrine/paracrine proliferative loop, IL-2 induces clone expansion and maintains survival of activatedT-cells. Third, after successful clearance of the pathogen, the stimulus for cytokines production is lostand activated T-cells thus will undergo apoptosis.

17

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

However, in autoimmune diseases, due to the persistence of autoantigen, autoreactive T-cells will be
activated and survive better. Autoreactive T-cell proliferation is involved in the pathogenesis of various
autoimmune diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). Artemether is apotent antimalarial drug. In 2007, Wang et al. found artemether significantly suppressed theproliferation and IL-2 and interferon-𝛾 (IFN-𝛾) production of T-cells triggered by TCR engagement.
Artemether significantly inhibited TCR engagement-triggered MAPKs signaling pathway including
phosphorylation of ERK1/2, Jnk, and P38. Authors further identified that artemether seriously affected
the function of T-cells, rather than the antigen-presenting cells (APCs) to exert the immunosuppressive
effects (Shi et al, 2015).
In their study, Shi et al (2015) concluded that artemisinin derivatives perform immunosuppressivefunctions primarily through inhibiting pathogenic T-cell activation, suppressing B cells activation andantibody production, and expanding regulatory T-cells ; the impact of artemisinins and derivatives on
different immune cells is shown in figure 2, Shi et al (2015) deem that, as anti-inflammatory agents,
artemisinin derivatives possess advantages to act on multiple checkpoints within the immune signalingcascade, with selectivity for activated pathogenic T-cells, to create a synergistic treatment effect on
disease activity. Thus, these artemisinin derivatives may be promising candidates to treat inflammation
and autoimmune disorders.
Gendrot et al (2020) conducted a study aimed to evaluate the antiviral activity of ACT at concentrations
consistent with those observed in human plasma when ACT is administered at oral doses foruncomplicated malaria treatment. In their estimations of the % of inhibition of the SARS-CoV-2
replication by fixed-doses of ACT, they found that Mefloquine-artesunate exerted the highest antiviral
activity with inhibition of 72.1 %.
These in vitro results presented by Gendrot et al (2020) reinforce the hypothesis that antimalarial drugs
would be effective as an anti-COVID-19 treatment. Based on their results, it would be expected thatcountries commonly using ACT report fewer cases and fewer deaths during malaria season.
It is imperative to evaluate the ACT efficacy clinically to treat COVID-19, particularly that of mefloquineartesunate, and the potential intervention of ACT against SARS-CoV-2, by comparing its antimalarial
use and the dynamics of COVID-19, country by country (Gendrot et al, 2020).

18

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Augustin et al (2020) reported that beyond its antimalarial effects, drug repurposing with artesunate
has shown cytotoxic effects against viruses, fungi, and a variety of cancers as well as powerful antiinflammatory effects. Several in vitro and in vivo models have demonstrated protective effects ofartesunate against multiple organ failure in models of lung, myocardial and renal injury via modulationof key pro-inflammatory pathways. Severe COVID-19 disease results in the generation of proinflammatory cytokines, including IL-6 and IL-1b, via the toll like receptors, resulting in the productionof active mature IL-1b, which is a mediator of fever, lung inflammation and fibrosis. There is acorrelation between IL-6 peak levels and severity of pulmonary complications.
Figure 2. Immunoregulatory and anti-Inflammatory actions of artemisinin and Its derivatives

Reference: Shi et al (2015)19

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Augustin et al (2020) concluded that the hallmark of severe COVID-19 infection is a severe
inflammatory response caused by a cytokine release syndrome of which pro-inflammatory cytokine IL6 is a key component. Respiratory distress syndrome, myocarditis and renal failure are cytokine release
syndrome/ cytokine storm sequelae with devastating effects. Artesunate is able to modulate proinflammatory cytokine pathways, and in doing so prevent multi-organ failure in models of lung,myocardial and renal injury. A safe and affordable treatment that could prevent patients with mild or
moderate COVID-19 infection progressing to severe infection, as a result of cytokine release syndrome/cytokine storm, would represent a significant breakthrough globally.
Ivermectin and Viral Inhibition
On April 3, 2020, a famous scientific publication by Caly et al (2020) was available online. It reported
that ivermectin, an FDA-approved anti-parasitic, previously shown to have broad-spectrum anti-viral
activity in vitro, is an inhibitor of the causative virus, SARS-CoV-2. A single addition of ivermectin to
Vero-hSLAM cells, 2 hours post infection with SARS-CoV-2, was able to effect ~5000-fold reduction inviral RNA at 48 h.
Since that publication of Caly et al (2020), an overwhelming amount of scientific studies and testimonies
around the entire globe have been reported about the efficacy of ivermectin. Here, a representative
report by Formiga et al (2020) of some of the work being done in Brazil is presented:
In light of the potential of ivermectin to prevent replication in a broad spectrum of viruses, Rocha
Formiga et al (2020) have discussed the inhibition of importin α/β1-mediated nuclear import of viralproteins as the probable mechanism underlying its antiviral activity. Since SARS-CoV-2 is an RNA
virus, a similar mechanism of action may take place. A possible ionophore role for ivermectin has also
been reported. Since ionophore molecules have been described as potential antiviral drugs, ivermectin
could ultimately induce an ionic imbalance that disrupts the potential of the viral membrane, thereby
threatening its integrity and functionality.
Formiga et al (2020) have illustrated that the pathology of COVID-19 is characterized by the rapid
replication of SARS-CoV-2, triggering an amplified immune response that may lead to cytokine storm,
which frequently induces a severe inflammatory pulmonary response. Disease progression may resultin progressive respiratory failure arising from alveolar damage and can lead to death. Moreover, the20Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

monitoring of SARS-CoV-2 viral load in the upper respiratory tract and bronchoalveolar lavage fluid(BALF) in patients with severe disease indicates higher loads, as well as greater viral persistence.
Regarding its anti-inflammatory properties, ivermectin has been shown to mitigate skin inflammation.
Importantly, ivermectin significantly diminished the recruitment of immune cells and cytokine productionin BALF assessed in a murine model of asthma. A study evaluating the ability of ivermectin to inhibit
lipopolysaccharide (LPS)-induced inflammation revealed significantly decreased production of TNFalpha, IL-1ss and IL-6 in vivo and in vitro. Further studies may establish the role of ivermectin in the
inflammatory response caused by SARS-CoV-2. Besides the antiviral activity ivermectin could play a
supportive adjuvant role facing the hostile infection microenvironment (Rocha Formiga et al, 2020).
Ivermectin Mode of Action
Gupta, Sahoo and Singh (2020) have reported that recently, the antiviral function of ivermectin has
been discovered, which appears to be intriguing. Already its effectiveness against certain flavivirus(dengue fever, Japanese encephalitis and tick-borne encephalitis virus) and chikungunya virus has
been demonstrated in vitro. Since then, the same activity has been assessed in numerous other viral
infections. Currently, its potency has been recognized in eliminating coronavirus in vitro. The exact
mechanism to which this effect can be attributed is yet to be validated. The speculated mechanism isinhibition of importin α/β1 mediated transport of viral proteins in and out of the nucleus. Importins, typesof karyopherins, exemplify a major class of soluble transport receptors which are involved in nucleocytoplasmic transit of various substrates. The speculated inhibitory action of ivermectin on importin
α/β1 mediated transport system explains the role of ivermectin in eliminating Covid-19 (Mastrangelo etal, 2012, Varghese et al , 2016, Tessier et al, 2019, Oka &Yoneda, 2018, Gupta, Sahoo and Singh,2020).
In a single in vitro study, the efficacy of ivermectin against coronavirus was demonstrated by Caly etal.(2020). The in vitro potency of ivermectin against Covid-19 virus is evidence that this drug can beutilized to manage patients infected with SARS-CoV-2. Upon comparison, Ivermectin may prove tohave leverage over the other pharmacotherapeutic options for the management of Covid-19.
Furthermore, the treatment regimen with Ivermectin is very cost-effective. Considering these merits, it
becomes imperative that multiple clinical trials with Ivermectin be conducted (Gupta, Sahoo and Singh,2020).
21

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

The Bangladesh Protocol for Ivermectin
Prof. Mohammed Tarek Alam, Professor and Head of Department of Medicine, Bangladesh Medical
College, was the lead author of this protocol. Alam et al (2020) carried out a prospective study in which
a combination of Ivermectin and Doxycycline was evaluated therapeutically to treat COVID-19 patients.
100 COVID-19 patients were enrolled in the study with a predefined inclusion and exclusion criteria.
RT- PCR of the SARS-CoV-2 were done at designated government hospitals. The clinical features andresponses to treatment were recorded according to a dedicated protocol.
Patients were given a combination therapy of Ivermectin and Doxycycline along with supportive medical
treatment. The dose of Ivermectin was 0.2 mg/kg as a single dose. Doxycycline 100 mg was given
once daily for 10 days (Alam et al, 2020).
This observational study, consisting of 64 males and 36 females, was conducted from April to May
2020 in Bangladesh Medical College. The oldest patient was 84 years and the youngest was 8 years,
with most patients between the ages of 21 to 40 years. Patients were divided into 3 groups: Mild (73),Moderate (20) and Severe (7), based on their symptoms. From the severe patients, 3 had fever higher
than 103 degrees Fahrenheit for seven days with severe cough and lung infiltrates, 3 had severe
diarrheal and 1 had uncontrolled diabetes. Of the rest, 20 patients had moderate symptoms of mild
fever (100 degrees Fahrenheit) and mild cough. Moreover, 73 had mild symptoms of malaise, sorethroat, loss of smell, loss of taste, and body ache. Fifty percent symptomatic improvement of mild tomoderate patients was seen between the 3rd to 5th day after starting treatment. By the 7th day oftreatment, all 7 severe patients’ symptoms subsided by 50 percent. Retesting was done between 4 18 days of starting medication. Twenty-five patients underwent retesting between the 4 - 8 days, 51
between the 9 -13 days and 24 between the 14 -18 days from starting medication. All the patients
tested negative. None needed intensive care admission and no deaths were reported. No toxicity wasseen with the drug at any point of time (Alam et al, 2020).
Dr. Borody’s Ivermectin Protocol
News Corp media is the latest major media to report on the proposal of Professor Thomas Borody.
This gastroenterologist received credit for developing the world’s first peptic ulcers cure, saving many
lives in the process. He is proposing ‘making Ivermectin available for at least those economically22

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

disadvantaged, vulnerable individuals, infected with COVID-19, without health care access, in an
endeavor to reduce the severity and duration of the novel coronavirus’. Professor Borody stepped up
to publicly declare this need, despite a great majority of health authorities who do not think much on
this topic. A few clinical trials have been completed (Bangladesh and Iraq), but because they havebeen on the smaller scale and TrialSite suspects (and this is just a speculation), because they originate
out of low-and middle-income countries (LMICs) health regulators and research elites in wealthiercountries are not paying attention. A real-world, observational off label initiative was deemed successful
in Broward County U.S., but no medical journals are willing to consider a review of the findings. Dr.
Borody broadcasted his concerns due to the complete lack of intellectual curiosity exhibited by amajority of the world’s leading research agencies and health authorities (TrialSite, 2020).
In the meantime, Shannon Molloy from News Australia was given the green light to write about
Ivermectin. TrialSite emphasizes this because a good many highly respected journalists working for
major media will not, at least up until this point, with no benefit from such a decision. The Sydney-based
Dr. Borody, now urges health authorities to consider an Ivermectin plan for at least A) low-and middleincome countries and B) the underdeveloped areas within developed countries (TrialSite, 2020).
Molloy reports that Dr Borody believes the “answer to Australia’s COVID-19 crisis” is what was termed
the Australian combination of Ivermectin, Doxycycline, and Zinc. Dr. Borody, a well-established andprominent figure suggests at least in Australia: A) these medicines are already approved by authorities
and proven safe and B) they do not need to go through any more preclinical research, or for that matter
clinical trials unless they are to be combined in a capsule (TrialSite, 2020).
Dr. Borody is the Study Director of a Clinical Trial of Combination Therapy to Treat COVID-19 Infection.
Patients in this trial will undergo treatment for 10 days with either a combination of therapies or placebo.
They will then be followed for 6 months. The intervention therapy is: Ivermectin, Doxycycline Hcl, Zinc,
Vitamin D3, Vitamin C.
Dr. Camargo Ivermectin Protocol
Dr. Antonio Camargo, Scientific Director of the Institute ONKOS, conducted a study on the use of highdoses of ivermectin in the treatment of infection by SARS-CoV2 (COVID-19), as a case of molecular23

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

resolution. He presented his experience and personal testimony about the use of Ivermectin to treat
himself. In his case, the treatment protocol, considering the high viral load presented in the moleculartest, augured a prognosis quite reserved and critical. Departing from this delicate situation, recovering
completely, the protocol was formulated as follows: 60 mg of Ivermectin for 4 days, followed by 30 mg
for 3 days, for a total of 330 mg in 7 days (Camargo, 2020).
Three days after starting treatment with 60 mg dose of Ivermectin daily, and after testing, it wasobserved that the viral load was completely negative, indicating complete disappearance of thepathogen after 3 days of treatment with this medicine (Camargo, 2020).
In this regard, sub-doses of Ivermectin should not be used, since this can cause the false impressionof achieving an effect. In any case, it merits to bet on the maximum tolerated and suggested doses inorder to eradicate the virus effectively and achieve rapid rates of cure (Camargo, 2020).
Camargo (2020) explained that it is therefore worth to note the studies carried out by Aránzazu
Gonzáles Canga et.al (2010), demonstrated remarkable safety using doses of Ivermectin, higher thanthose suggested. Doses of 1000ug / kg for 3 days, for example, showed no adverse effects, even withadditional doses of 200ug / Kg there were no problems, highlighting that the drug's metabolism is widelydistributed, mainly in hepatic peroxisomes.
With his own study (Case Report), Camargo assures that he has evidence that Ivermectin represents,
so far, the most powerful and effective "coronicidal" agent that exists for the rapid treatment and attackof the pathogen. Therefore he maintains that the application deserves to be massive in the face of thethreat of the pandemic, since its use is simple to apply and far superior, in terms of safety andtoxicological profile, compared to other drugs.
Broward County (South Florida) Ivermectin Protocol
Rajter et al (2020), at the Broward Health Medical Center, followed on a retrospective cohort study ofconsecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed
SARS-CoV-2. Two hundred and eighty patients with confirmed SARS-CoV-2 infection (mean age 59.6
years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107
given usual care, were reviewed. Twenty seven identified patients were not reviewed due to multiple
24

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

admissions, lack of confirmed COVID results during hospitalization, under 18 years of age, pregnancy,
or incarceration. Exposure: Patients were categorized into two treatment groups based on whether
they received at least one oral dose of Ivermectin at 200 micrograms/kilogram at any time during the
hospitalization in addition to those receiving usual clinical care. Treatment decisions were at thediscretion of the treating physicians. Rajter et al (2020) concluded that Ivermectin was associated withlower mortality during treatment of COVID-19, especially in patients who required higher inspired
oxygen or ventilatory support. The authors suggested these findings should be further evaluated withrandomized controlled trials.
Mass Administration of Ivermectin
Mass Drug Administration (MDA) consisting of administering, at regular intervals, a full antimalarial
treatment to the whole population, in this case several African Countries that follow MDA of ivermectin,
will be analyzed for the COVID-19 impact.
Dihydroartemisinin (also known as dihydroqinghaosu, artenimol or DHA) is a drug used to treat malaria.
Dihydroartemisinin is the active metabolite of all artemisinin compounds (artemisinin, artesunate,artemether, etc.) and is also available as a drug, in itself. It is a semi-synthetic derivative of artemisininand is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs(Woo, 1998). It is sold commercially in combination with piperaquine and has been shown to beequivalent to artemether/lumefantrine (Arinaitwe et al, 2009). African countries such as Senegal,
Burkina Faso, Liberia, Tanzania, etc. have achieved excellent results with ivermectin anddihydroartemisinin-piperaquine (Foy et al. 2019; Romani et al. 2019; Alout, Haoues. 2014).
The WHO (2016) reported that in 2014 alone, more than 260 million people were treated with ivermectinfor onchocerciasis/ Lymphatic Filariasis (LF). Due to its success, the LF programme has been
downscaled in 11 countries. The global demand for ivermectin is expected to grow due to additional
indication for scabies and new evidence that a single dose of Ivermectindiethylcarbamazine (DEC)albendazole can accelerate LF elimination. Ivermectin is currently donated to countries’ NTD
programmes through the Mectizan® donation programme. The main delivery strategy is throughcommunity volunteers annually, semiannually, or quarterly.

25Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

The Madagascar Protocol
The U.S. President's Malaria Initiative (PMI)—led by the U.S. Agency for International Development(USAID) and implemented together with the U.S. Centers for Disease Control and Prevention (CDC),
delivers cost-effective, lifesaving malaria interventions alongside catalytic technical and operational
assistance to support Madagascar to end malaria (MOP, 2020).
This Malaria Operational Plan (MOP) outlines planned PMI activities in Madagascar for Fiscal Year
2020. Developed in consultation with the National Malaria Control Program (NMCP) and key
stakeholders, proposed activities reflect national and PMI strategies, draw on best-available data, andalign with the country’s context and health system. Proposed PMI investments support and build on
those made by the Government of Madagascar, as well as other donors and partners (MOP, 2020).
PMI organizes its activities and planning levels around the activities, in line with the national malaria
strategy. One of the activities has to do with Diagnosis and Drug Based Prevention. The treatment formalaria includes Artemisinin Based Combination Therapies (ACT) plus primaquine (MOP, 2020). ACTs
are the mainstay of recommended treatment for P. falciparum malaria (WHO, 2020). Artemisinin isisolated from the plant Artemisia annua, sweet wormwood, a herb employed in Chinese traditional
medicine to treat malaria. According to MOP (2020) the first-line treatment is artesunate-amodiaquine(ASAQ), and second-line treatment is artemether-lumefantrine (AL). According to the country’s casemanagement guidelines, P. vivax malaria should be treated with ASAQ followed by a 14-day course of
primaquine. Severe malaria cases are treated with injectable artesunate followed by ACT. Rectal
artesunate was recently introduced at the community level for pre-referral treatment of children lessthan five years of age (CU5) with severe disease. It is important to keep in mind that artesunate andartemether are semisynthetic derivatives of artemisinin, an antimalarial drug.
The Malaria Operational Plan operates both nationally and in support of the National Malaria Control
Program, planning policies and malaria commodities, with direct program support in 10 regions of thecountry, covering a population of approximately 12,500,000 (MOP, 2020). This is what is known as
Mass Drug Administration (MDA).
The President of Madagascar, Andry Rajoelina, officially launched a natural medicine he believes canprevent and cure people suffering from COVID-19. Developed by the Malagasy Institute of Applied
26

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Research and branded COVID Organics, President Rajoelina presented the remedy to the press. It
contains Artemisia, a plant cultivated and exported on the Big Island to fight against malaria. “All trials
and tests have been conducted and its effectiveness in reducing and eliminating symptoms has been
proven for the treatment of patients with COVID-19 in Madagascar,” the president said. Humanity isliving an ongoing dramatic story where its survival is at risk. We do not have the luxury of turning ourbacks to a healing plant that already has shown excellent medicinal properties for thousands of years(Abreu, 2020).
A Final Analysis
Clear age trends in coronavirus deaths have been reported since early in the pandemic. Researchteams looking at the presence of antibodies against SARS-CoV-2 in people in the general populationin Spain, England, Italy, and Geneva in Switzerland, have now quantified that risk. It gives us a muchsharper perspective when asking what the impact might be on a certain population that have a certain
demographic (Mallapaty, 2020).
For every 1,000 people infected with the coronavirus who are under the age of 50, almost none willdie. For people in their fifties and early sixties, about 5 out of 1000 will die - more men than women.
The risk climbs steeply as the years accrue. For every 1,000 people in their mid-seventies or older who
are infected, around 116 will die. These are the stark statistics obtained by some of the first detailed
studies into the mortality risk for COVID-19 (Mallapaty, 2020).
The countries compared in this research are:
The United States of America (USA), Mexico, Canada, Francia, Madagascar, and in addition the World
global data, was taken as a reference. The data used was from the period of April 2020 to Nov 02,
2020.
Cambaza (2020) explained that COVID-19 is not spreading quickly in Sub-Saharan regions, possibly
due to a combination of several factors, one being the predominance of younger populations. In thepresent analysis, the age factor has no impact on the calculations.
In the study, Madagascar showed the highest percentage of younger population, while Canada showed
the lowest percentage. For this reason, to minimize the impact of the age factor in the comparative27

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

analysis of this study, the age factor was standardized in the countries analyzed, to a population of 25
years and over (Table 1).

In table 1, based on data from WHO and the World Factbook (2020), Madagar´s Deaths per Million(23) is compared with the World (255), the USA (987), Mexico (1,299), Canada (379), France (620)
and the World (255). The calculated differences that significantly surpass Madagascar in number ofdeaths per million are:
 USA: 987-23= +964
 Mexico: 1,299-23= +1,276
 Canada: 379-23= +356
 France: 620-23= +597
 World: 255-23= +232
Departing from these results of the analysis, and taking as a reference the Madagascar factor, it canbe hypothesized about lives that could have been saved:
 USA: 217,033
 Mexico: 90,14028

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

 Canada: 9,346
 France: 28,117
 World: 1,033,821
Dr. Marcel Razanamparany (2020), President of the National Academy of Medicine of Madagascar,
expressed that in a race against time to find a cure for COVID-19, Madagascar began early therapies
associated with treatments derived from traditional knowledge with emphasis on the use of medicinal
plants. With Madagascar’s rich biodiversity and the central role of its traditional practitioners, thedecision was made to promote traditional medicine (The African Report, 2020).
It was announced by Razanamparany (2020) that under the presidential coordination of Madagascar
for the use of Artemisia annua against the coronavirus, the Malagasy Institute of Applied Research(IMRA) and the National Pharmacology Research Centre joined forces to conduct studies and set up
a research protocol on this plant already known for its virtues against malaria. This led to thedevelopment of Covid-Organics, an improved traditional remedy made up of artemisia. Abundant on
Malagasy soil, the artemisia annua has already been the subject of more than twenty studies in
Madagascar where it was introduced in 1975 by Professor Albert Rakoto Ratsimamanga to fight against
malaria.
The research protocol enabled the IMRA team, which has been working on this plant for a long time,to verify its good results in reducing and eliminating coronavirus symptoms. This is another discovery
for this research centre, which has some fifty remedies to its credit, developed by combining traditionaland modern medicine, including the antidiabetic drug Madeglucyl and the cough supressant Madetoxin(Razanamparany, 2020).
This medical and pharmaceutical research and training centre, IMRA, was founded in 1957 thanks to
the financial benefits of a healing drug, Madecassol, which its founders Albert and Suzanne Rakoto
Ratsimamanga derived from the centella asiatica plant. The centre is nationally and internationallyrenowned and has been granted the status of regional research centre by the African Union(Razanamparany, 2020).
IMRA is located in Antananarivo and composed of a team of about a hundred people, including somethirty researchers and technicians, its research focuses on phytochemistry, parasitic and cellular29

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

pharmacology, experimental diabetology, pharmacodynamics, toxicology and the analytical chemistryof essential oils. It was recognized as being of public utility by the Government Council on 2 October
2012 (Razanamparany, 2020).
IMRA has aimed to adopt an approach to scientific research that integrates health care, biodiversity
conservation, and production. In the course of its work, IMRA has advocated practices that protect theenvironment, respect local culture, and empower local populations to share in the economic benefitsof bioprospecting. IMRA’s relationship to traditional Malagasy healing has been important to theorganization’s achievements to date (Puri, Masum and Heys, 2010).
The development of Covid-Organics has been explained by Razanamparany (2020). It is a perfectillustration of the credo of Professor Albert Rakoto Ratsimamanga, whose research focused on the
combination of traditional and modern medicine. Regarded as the pioneer of science in Madagascar,this researcher, who was at the origin of some 350 scientific studies, declared: “We must move forward
at our own pace, we must above all have confidence in ourselves and in the therapeutic virtues ofnature. For nature and man are one.”The data presented in this research paper exemplify how Madagascar has turned into a profound,ongoing global research study, providing scientific evidence in real time within populated communities.
Its significance, relative to sectorized conventional clinical trials needs to be recognized.
It is time to acknowledge Madagascar for their insightful contribution to the scientific world andhumanity.
ACKNOWLEDGEMENT
The author is grateful to Dr. Jennifer Hibberd for insights that helped shape the content and structureof the article and for her valuable help in editing and refining it. In addition, the author would like tothank her for these wonderful words: “You’ve written an important paper. It will guide many in research& therapy. I am proud to be associated with your work as your colleague & editor”.

30Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

INVITATION
The author would like to kindly invite you to visit the following sites:
Research on the Madagascar Protocol and Coronavirus. Educational Research Center
HIBBERD HEALTH Dr Jennifer Hibberd

Book on Artemisia annua

References
Abreu, Jose Luis. 2020. Artemisia Annua Research: Antiviral Properties Paperback. Independently
published. ISBN-13: 979-8651709663
Abreu, Jose Luis. 2020. The Madagascar Protocol (Artemisia annua) & Ivermectin for the Treatmentof COVID-19: It is not a Miracle, it is Plain Science. Daena: International Journal of Good Conscience.
15(2)1-18. September 2020. ISSN 1870-557X
Akaike, T., Noguchi, Y., Ijiri, S., Setoguchi, K., Suga, M., Zheng, Y. M., Dietzschold, B., and Maeda, H.
(1996) Proc. Natl. Acad. Sci. USA, 93, 2448-2453.
Akaike, T., Suga, M., and Maeda, H. (1998) Proc. Soc. Exp. Biol. Med., 217, 64-73.
Alout, Haoues. 2014. Evaluation of ivermectin mass drug administration for malaria transmission
control across different West African environments. Malaria Journal 2014, 13:417.
Anis Abobaker. 2020. Reply: Iron chelation may harm patients with COVID-19. Letter to the editor.
European Journal of Clinical Pharmacology. Received: 12 August 2020 /Accepted: 27 August 202031

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Arinaitwe, Emmanuel; Sandison, Taylor G.; Wanzira, Humphrey; Kakuru, Abel; Homsy, Jaco;
Kalamya, Julius; Kamya, Moses R.; Vora, Neil; et al. (2009). "Artemether‐Lumefantrine versus
Dihydroartemisinin‐Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young
Ugandan Children". Clinical Infectious Diseases. 49 (11): 1629–37. doi:10.1086/647946. PMID
19877969.
Athar Ali, Abdul Qadir, Mather Ali Khan, Parul Saxena, and Malik Zainul Abdin.2018. Mode of Actionof Artemisinin. Chapter 14. In Tariq Aftab, M. Naeem & M. Masroor A. Khan. 2018. Artemisia annua.
Prospects, Applications and Therapeutic Uses. 2018. CRC Press. Taylor & Francis Group. ISBN 13:
978-1-138-63210-3
Attilio Cavezzi, Emidio Troiani, Salvatore Corrao. 2020. COVID-19: hemoglobin, iron, and hypoxia
beyond inflammation. A narrative review. Clinics and Practice 2020; volume 10:1271
Barry Halliwell, Marie Veronique Clement, Lee Hua Long. 2000. Hydrogen peroxide in the human body.
FEBS Letters 486.
Borody, Thomas. 2020. More News on Dr. Borody’s Ivermectin
https://www.trialsitenews.com/more-news-on-dr-borodys-ivermectin-proposal/

proposal.

Camargo, Antonio. 2020. La Ivermectina: Altas dosis en el tratamiento de infección por SARS-CoV2(COVID-19): Un caso de resolución molecular. http://www.onkos.pe/category/estudios
Carlo Perricone, Elena Bartoloni, Roberto Bursi, Giacomo Cafaro, Giacomo Maria Guidelli, Yehuda
Shoenfeld, Roberto Gerli. 2020. COVID-19 as part of the hyperferritinemic syndromes: the role of irondepletion therapy. Immunologic Research (2020) 68:213–224.
Chenchen Shi, Haipeng Li, Yifu Yang, and Lifei Hou. 2015. Anti-Inflammatory and Immunoregulatory
Functions of Artemisinin and Its Derivatives. Hindawi Publishing Corporation Mediators of Inflammation
Volume 2015, Article.
D’Alessandro Sarah, Diletta Scaccabarozzi, Lucia Signorini, Federica Perego, Denise P. Ilboudo,
Pasquale Ferrante and Serena Delbue. 2020. The Use of Antimalarial Drugs against Viral Infection.
Microorganisms 2020, 8, 85; doi:10.3390/microorganisms8010085
Edeas M, Saleh J, Peyssonnaux C (2020) Iron: Innocent bystander or vicious culprit in COVID-19
pathogenesis? Int J Infect Dis 97:303–305
Fabio Rocha Formiga, Roger Leblanc, Juliana de Souza Rebouças, Leonardo Paiva Farias, Ronaldo
Nascimento de Oliveira, Lindomar Pena. 2020. J Control Release. 2020 Oct 7.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539925/
Falciani, F., Ghezzi, P., Terao, M., Cazzaniga, G., and Garattini, E. (1992) Biochem. J., 285, 10011008.

32

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Foy BD et al. 2019. Efficacy and risk of harms of repeat ivermectin mass drug administrations forcontrol of malaria (RIMDAMAL): A cluster randomised trial. Lancet. Mar. [e-pub].
Furuke, K., Sasada, T., Ueda-Taniguchi, Y., Yamauchi, A., Inamoto, T., Yamaoka, Y., Musutani, H.,
and Yodoi, J. (1997) Cancer Res., 57, 4916-4923.
Garrick M, Ghio A (2020) Iron chelation may harm patients with COVID-19. Eur J Clin Pharmacol
Gupta, D. et al. Ivermectin: potential candidate for the treatment of COVID19. Braz J Infect Dis. 2020.
Haynes RK, Cheu KW, N'Da D, Coghi P, Monti D. 2013. Considerations on the mechanism of actionof artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses. Infect Disord Drug
Targets. 2013 Aug;13(4):217-77.
Henderson, M. I., and Chappell, J. B. (1996) Biochim. Biophys. Acta, 1273, 87-107.
Ian Huang; Raymond Pranata; Michael Anthonius Lim; Amaylia Oehadian and Bachti Alisjahbana.
2020. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a
meta-analysis. Therapeutic Advances in Respiratory Disease. 2020, Vol. 14: 1–14
Ivan A. Yaremenko, Vera A. Vil’, Dmitry V. Demchuk and Alexander O. Terent’ev. 2016.
Rearrangements of organic peroxides and related processes. Beilstein J. Org. Chem. 2016, 12, 1647–
1748
Jenifer Gómez-Pastora, Mitchell Weigand, James Kim, Xian Wu, Jacob Strayer, Andre F. Palmer,
Maciej Zborowski, Mark Yazer, Jeffrey J. Chalmers. 2020. Hyperferritinemia in critically ill COVID-19
patients – Is ferritin the product of inflammation or a pathogenic mediator? Clinica Chimica Acta.
Volume 509, October 2020, Pages 249-251.
Jigang Wang, Chengchao Xu, Yin Kwan Wong, Yujie Li, Fulong Liao, Tingliang Jiang, Youyou Tu.
2019. Artemisinin, the Magic Drug Discovered from Traditional Chinese Medicine. Engineering 5 (2019)32–39.
Juliana Cepelowicz Rajter, Michael Sherman, Naaz Fatteh, Fabio Vogel, Jamie Sacks, Jean-Jacques
Rajter, 2020. COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv. ICON (Ivermectin in COVID
Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with
COVID19. https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2
Kate F. Kernan, and Joseph A. Carcillo. 2017. Hyperferritinemia and inflammation. International
Immunology, Vol. 29, No. 9, pp. 401–409. doi:10.1093/intimm/dxx031. Advance Access publication 25
May 2017.
Katsunori Tsuda, Licht Miyamoto, Shuichi Hamano, Yuri Morimoto, Yumi Kangawa, Chika Fukue,
Yoko Kagawa, Yuya Horinouchi, Wenting Xu, Yasumasa Ikeda, Toshiaki Tamaki, and Koichiro
Tsuchiya. 2018. Mechanisms of the pH- and Oxygen-Dependent Oxidation Activities of Artesunate.
Biol. Pharm. Bull. 41, 555–563 (2018).
33

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Leon Calya, Julian D. Drucea, Mike G. Cattona, David A. Jansb, Kylie M. Wagstaffb. 2020. The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. Volume
178, June 2020, 104787
Liu W, Zhang S, Nekhai S, Liu S (2020) Depriving iron supply to the virus represents a promising
adjuvant therapeutic against viral survival. Curr Clin Microbiol Rep 7(2):13–19
Maeda, H., and Akaike, T. (1998) Biochemistry (Moscow), 63, 1007-1019 (Russ.).
Mahsa Rahbari, Stefan Rahlfs, Esther Jortzik, Ivan Bogeski, Katja Becker. 2017. H2O2 dynamics inthe malaria parasite Plasmodium falciparum. PLoS ONE 12(4): e0174837.
https://doi.org/10.1371/journalpone.0174837
Malaria Operational Plan (MOP). 2020. U.S. President’s Malaria Initiative 2020. Madagascar.
www.pmi.gov
Manveen Puri, Hassan Masum, Jennifer Heys, Peter A Singer. 2010. Harnessing biodiversity: theMalagasy Institute of Applied Research (IMRA). Puri et al. BMC International Health and Human Rights
2010, 10(Suppl 1):S9
Marcel Razanamparany. 2020. Coronavirus: Madagascar’s ‘Covid-Organics’ born from local tradition.
The Africa Report. President of the National Academy of Medicine of Madagascar.
https://www.theafricareport.com/27203/coronavirus-madagascars-covid-organics-born-from-localtradition/
Mathieu Gendrot, Isabelle Duflot, Manon Boxberger, Océane Delandre, Priscilla Jardot, Marion Le
Bideau, Julien Andreani , Isabelle Fonta, Joel Mosnier, Clara Rolland, Sébastien Hutter, Bernard La
Scola, Bruno Pradines. 2020. Antimalarial artemisinin-based combination therapies (ACT) and COVID19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.
Mentel' R, Shirrmakher R, Kevich A, Dreĭzin RS, Shmidt. 1977. Virus inactivation by hydrogen peroxide.
Voprosy Virusologii, 31 Oct 1977, (6):731-733.
Michelle Finnegan, Ezra Linley, Stephen P. Denyer, Gerald McDonnell, Claire Simons and Jean-Yves
Maillard. 2010. Mode of action of hydrogen peroxide and other oxidizing agents: differences between
liquid and gas forms. Journal of Antimicrobial Chemotherapy · October 2010.
MT Alam, R Murshed, E Bhiuyan, S Saber, RF Alam, RC Robin. 2020. Journal of Bangladesh Collegeof Physicians and Surgeons Vol. 38, COVID-19 (Supplement Issue), July 2020.
Nai-Di Yang; Shi-Hao Tan; Shukie Ng; Yin Shi; Jing Zhou; Kevin Shyong Wei Tan; Wai-Shiu Fred
Wong; Han-Ming Shen. 2014. Ferritin degradation in artesunate-induced cell death. The American
Society for Biochemistry and Molecular Biology, Inc.
Nakanura, H., Furuke, K., Matsuda, M., Inamoto, T., and Yodoi, J. (1995) Adv. Exp. Biol. Med., 371B,
909-911.
34

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Roederer, M., Ela, S. W., Staal, F. J., Herzenberg, L. A., and Herzenberg, L. A. (1992) AIDS Res. Hum.
Retroviruses, 8, 209-217.
Skulachev, V. P. (1996) Quart. Rev. Biophys., 29, 169-202.
Skulachev, V. P. (1997) Biosci. Rep., 17, 347-366.
Skulachev, V. P. (1998) in Bioscience-2000 (Pasternak, C. A., ed.) World Sci. Publ., Singapore London,in press.
Skulachev, V. P. 1998. Possible Role of Reactive Oxygen Species in Antiviral Defense. Biochemistry(Moscow)
On-Line.
Volume63.
ISSN:
1608-3040(Online).
http://protein.bio.msu.ru/biokhimiya/contents/v63/full/63121691.html
Staal, F. J., Roederer, M., Herzenberg, L. A., and Herzenberg, L. A. (1990) Proc. Natl. Acad. Sci. USA,87, 9943-9947.
Tariq Aftab, M. Naeem & M. Masroor A. Khan. 2018. Artemisia annua. Prospects, Applications andTherapeutic Uses.
TrialSite. 2020. Ivermectin. https://www.trialsitenews.com/
Vargas-Vargas M and Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Publica.
2020;44:e72. https://doi. org/10.26633/RPSP.2020.72
Vera A. Vil’, Ivan A. Yaremenko, Alexey I. Ilovaisky and Alexander O. Terent’ev. 2017. Peroxides with
Anthelmintic, Antiprotozoal, Fungicidal and Antiviral Bioactivity: Properties, Synthesis and Reactions.
Molecules 2017, 22, 1881; doi:10.3390/molecules22111881
Vora, Agam; Arora, V.K. and Behera, D. 2000. White paper on Ivermectin as a potential therapy for
COVID-19. Indian J Tuberc. 2020 Jul; 67(3): 448–451.
World Factbook. 2020. CIA. https://www.indexmundi.com/
World Health Organization (WHO). 2016. Ivermectin for malaria transmission control. Malaria Policy
Advisory Committee Meeting. 14–16 September 2016, Geneva, Switzerland. Background documentfor Session 9
World Health Organization (WHO). 2020. “Solidarity” clinical trials for COVID-19 treatments. Available
at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novelcoronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
Yodoi, J., and Uchiyama, T. (1992) Immunol. Today, 13, 405-410.
Yolanda Augustin, Henry Staines, Adeeba Kamarulzaman, Hans Platteeuw, Sanjeev Krishna. 2020.
Artesunate may attenuate the effects of Cytokine Release Syndrome (CRS) in Covid. Institute of35

Daena: International Journal of Good Conscience. V15-N3-A1(1-36). November 2020. ISSN 1870-557X

Infection & Immunity, St George’s University of London, United Kingdom. Faculty of Medicine,
University of Malaya, Malaysia. Avivia BV, The Netherlands.

ABOUT THE AUTHOR
Dr. Jose Luis Abreu is an independent researcher in the field of Phytochemistry. He is also a ResearchProfessor in the field of management science at The Business Faculty--Universidad Autonoma deNuevo León (UANL) and President of Spenta University Mexico (Monterrey, Mexico).
This study was funded with independent resources. There is not conflict of interest in this publication.
Email: spentamexico@gmail.com

36